TYRO3 and neoplasm: Mertk-/-, Axl-/- and Tyro3-/- tumor models were revealed to reduce RTK enzymatic activity, exhibit defective MDSC roles, and display poor tumor migration capacity to tumor-draining lymph nodes (TDLN) (70).